- Waters and Princeton University signed a multi-year agreement to take on real-world challenges in biologics and materials research.
- Initial collaboration will bring together Waters scientists with Princeton faculty and students to advance research in drug discovery and development using novel bioseparation techniques.
- Additional joint research areas may include higher purity pharmaceuticals, advanced analytical workflows, materials science, and advancements in drug development.
MILFORD, Mass. — Waters Corporation (NYSE: WAT) announced a multi-year research collaboration with Princeton University that will enable scientists, faculty, and students to work together to bring their diverse skills and backgrounds to solve complex challenges in biochemistry and materials science.
“Solving the biggest challenges in science takes collaborations that bring together diversity of thought and expertise. Our partnership with Princeton University seeks to enable powerful research in biochemical and advanced materials engineering,” said Dr. Udit Batra, President and CEO, Waters Corporation. “Together our initial work will focus on improving LC-MS workflows and sample preparation to enable our customers to conduct simpler and faster analyses with even greater precision. In turn, this will help biopharma scientists deliver therapeutics that are safe and highly effective for the treatment of disease, such as oncology and autoimmune diseases.”
“As a leading global institution of research and teaching, Princeton welcomes collaborations with industry to enrich education and accelerate research and innovation for societal benefit,” said Craig Arnold, Princeton University Vice Dean for Innovation and the Susan Dod Brown Professor of Mechanical and Aerospace Engineering. “We involved many Princeton faculty in our conversations with Waters as we considered this new relationship, and we were delighted to identify numerous initial research topics of mutual interest that build on Princeton’s research strengths in bioengineering and materials science and the distinctive capabilities of the Princeton Bioengineering Initiative (PBI). We believe our research collaborations will advance science, as well as offer new opportunities to our faculty and students.”
Under the new agreement, the Waters-Princeton collaboration will bring together academic and industry researchers to tap into knowledge and expertise from various scientific domains and disciplines to identify and solve problems that matter. One such research project will focus on novel media for purification to help advance drug development and discovery.
- Learn more about Innovation at Waters
- Learn more about bioengineering at Princeton University
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters is a trademark of Waters Corporation.
Senior Manager, Public Relations